Bactericidal activities of daptomycin, quinupristin-dalfopristin, and linezolid against vancomycin-resistant Staphylococcus aureus in an in vitro pharmacodynamic model with simulated endocardial vegetations.
about
Short-course gentamicin in combination with daptomycin or vancomycin against Staphylococcus aureus in an in vitro pharmacodynamic model with simulated endocardial vegetations.Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children.Daptomycin bactericidal activity and correlation between disk and broth microdilution method results in testing of Staphylococcus aureus strains with decreased susceptibility to vancomycin.Rapid bactericidal activity of daptomycin against methicillin-resistant and methicillin-susceptible Staphylococcus aureus peritonitis in mice as measured with bioluminescent bacteria.Lipopeptides, focusing on daptomycin, for the treatment of Gram-positive infections.Staphylococcus aureus with reduced susceptibility to vancomycin.Daptomycin - a novel antibiotic against Gram-positive pathogens.Gram-positive resistance: pathogens, implications, and treatment options: insights from the Society of Infectious Diseases Pharmacists.Update on daptomycin: the first approved lipopeptide antibiotic.Bacteremia and endocarditis due to methicillin-resistant Staphylococcus aureus: the potential role of daptomycin.Emerging options for treatment of invasive, multidrug-resistant Staphylococcus aureus infections.Daptomycin is effective in treatment of experimental endocarditis due to methicillin-resistant and glycopeptide-intermediate Staphylococcus aureus.Daptomycin: a rapidly bactericidal lipopeptide for the treatment of Gram-positive infections.Perspectives on Daptomycin resistance, with emphasis on resistance in Staphylococcus aureus.Daptomycin pharmacokinetics in adult oncology patients with neutropenic feverEvaluation of Pharmacodynamic Interactions Between Telavancin and Aztreonam or Piperacillin/Tazobactam Against Pseudomonas aeruginosa, Escherichia coli and Methicillin-Resistant Staphylococcus aureus.Impact of high-inoculum Staphylococcus aureus on the activities of nafcillin, vancomycin, linezolid, and daptomycin, alone and in combination with gentamicin, in an in vitro pharmacodynamic model.Treatment strategies for infective endocarditis.A case of staphylococcal tricuspid valve endocarditis with para-aortic abscess in a patient with bicuspid aortic valve.Evaluation of telavancin activity versus daptomycin and vancomycin against daptomycin-nonsusceptible Staphylococcus aureus in an in vitro pharmacokinetic/pharmacodynamic modelIn vitro pharmacodynamics of human simulated exposures of ceftaroline and daptomycin against MRSA, hVISA, and VISA with and without prior vancomycin exposureIn vitro resistance studies with bacteria that exhibit low mutation frequencies: prediction of "antimutant" linezolid concentrations using a mixed inoculum containing both susceptible and resistant Staphylococcus aureus.Activities of high-dose daptomycin, vancomycin, and moxifloxacin alone or in combination with clarithromycin or rifampin in a novel in vitro model of Staphylococcus aureus biofilm.Pharmacokinetic-pharmacodynamic modeling of the in vitro activities of oxazolidinone antimicrobial agents against methicillin-resistant Staphylococcus aureus.Pharmacokinetic/pharmacodynamic factors influencing emergence of resistance to linezolid in an in vitro model.Daptomycin for treating infected diabetic foot ulcers: evidence from a randomized, controlled trial comparing daptomycin with vancomycin or semi-synthetic penicillins for complicated skin and skin-structure infections.Pharmacokinetics and pharmacodynamics of linezolid in obese patients with cellulitis.Linezolid for the treatment of a heteroresistant Staphylococcus aureus shunt infection.Daptomycin-rifampin for a recurrent MRSA joint infection unresponsive to vancomycin-based therapy.Testing the mutant selection window hypothesis with Staphylococcus aureus exposed to linezolid in an in vitro dynamic model.
P2860
Q33883648-3C18B663-8B2A-484F-A46D-E55C8C04CB1CQ34157657-206E5CE2-1A38-4677-B5FE-ED0BF76D0B58Q34721715-76EEE4CA-2EA0-42CF-B574-F84DF38CC3AEQ35759049-08F1065E-9C75-4322-BEFF-0FD02D176CC5Q35871928-C7C54BE7-8385-46EA-9A9B-5AE71C579FA6Q35882353-9CB3CF5B-9BEB-49F7-8D1A-98540438A065Q35925535-BABA4C1F-9CA1-4996-B70E-F660114F64DBQ36188333-BD63F778-97AA-4936-AB8B-B60E82D0B49DQ36521880-91B921A9-44C6-404C-B886-108B3ABCBAA3Q36642946-4A55FD9F-BE63-4E95-A412-C81F1E0E0502Q36718474-E110EDA1-BA80-4247-9BD8-EBDF47897514Q36744825-FD5DA0B3-58BB-45B6-9FB4-205F3F750962Q36777821-82F7CC9A-E43F-4F8F-A86B-DDA44E62B9A0Q36903680-139A07B3-04E9-40A8-BE88-FAC2E3E13086Q37072100-E2F3998F-AA31-48BF-9962-8877FCB34480Q37250189-C4D05D0E-89E9-47C2-B826-187484391158Q37625071-F7E30A64-ECC5-4406-BADB-2F43D5AD2FA6Q37681564-A75CFDC1-D5E8-46BA-A2B3-F6FD165DAD0DQ37939120-763320C6-5B6F-4F25-A627-CCFA66CAACD4Q40602795-3ADFB314-3F80-4B66-A850-99A710596398Q41825567-4F817CD4-BC3B-4EFA-9CBF-13FAD6638D1EQ41850136-11EEED69-F27B-4317-BA23-55348B2DB1CBQ42111239-F837D3CF-D2A9-4F4D-A990-8A73BD039A51Q42687502-93504FB0-2C3B-4250-8BB6-B4A2A1210843Q42846091-640EE21D-D280-4DA9-9971-B481A6455492Q45230598-C870A8A6-D3B3-4A29-B52C-4431E75D3C14Q45258208-8E32FC85-496E-45C7-A858-8E6FBA6B0966Q46533720-D32B987D-758F-41BF-84F2-1EF18D2EA687Q46921060-7E06D634-404B-4D01-A146-B85D87CE1BCFQ49578631-887B4457-3E1B-4237-BE5B-C5CD6E24EA4C
P2860
Bactericidal activities of daptomycin, quinupristin-dalfopristin, and linezolid against vancomycin-resistant Staphylococcus aureus in an in vitro pharmacodynamic model with simulated endocardial vegetations.
description
2003 nî lūn-bûn
@nan
2003 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Bactericidal activities of dap ...... lated endocardial vegetations.
@ast
Bactericidal activities of dap ...... lated endocardial vegetations.
@en
Bactericidal activities of dap ...... lated endocardial vegetations.
@nl
type
label
Bactericidal activities of dap ...... lated endocardial vegetations.
@ast
Bactericidal activities of dap ...... lated endocardial vegetations.
@en
Bactericidal activities of dap ...... lated endocardial vegetations.
@nl
prefLabel
Bactericidal activities of dap ...... lated endocardial vegetations.
@ast
Bactericidal activities of dap ...... lated endocardial vegetations.
@en
Bactericidal activities of dap ...... lated endocardial vegetations.
@nl
P2093
P2860
P1476
Bactericidal activities of dap ...... lated endocardial vegetations.
@en
P2093
Michael J Rybak
Raymond Cha
William J Brown
P2860
P304
P356
10.1128/AAC.47.12.3960-3963.2003
P407
P577
2003-12-01T00:00:00Z